Krystal Biotech, Inc. (KRYS) Institutional Ownership

Ownership Summary

Krystal Biotech, Inc. (NASDAQ:KRYS) has 326 institutional investors that have filed 13F reports for the period ending December 2025.

• They owned 93.3% of outstanding stock in December 2025, down from 94.9% the prior quarter.
• They increased total shares held in Krystal Biotech by 1.26% from the prior quarter, while the number of investors in KRYS increased 25.38% year over year.
• During the quarter, 188 of these 326 funds increased positions in KRYS, 104 reduced exposure, and 34 held steady.
• Altogether, these fund groups held 27.96Mn shares in KRYS by December 2025, up by 348.91K shares quarter on quarter, and down 452.57K shares year over year.
• FMR LLC leads ownership in KRYS with 4.35Mn shares as of December 31, 2025, equal to 14.52% of outstanding shares.
• The most significant purchases of KRYS for the quarter ending December 2025 came from Bellevue Group AG (409.01K), NORGES BANK (284.57K), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (227.04K), Janus Henderson Group Plc (209.37K), Avoro Capital Advisors LLC (111.11K).
• The largest sales of KRYS for the quarter ending December 2025 came from BRAIDWELL LP (318.3K), CITADEL ADVISORS LLC (250.48K), Frazier Life Sciences Management, L.P. (200.0K), UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (168.97K), Jpmorgan Chase & Co (158.08K).
• Per Business Quant, the top 10 investors in KRYS for the quarter ending December 2025 include FMR LLC (4.35Mn), BlackRock, Inc. (3.94Mn), Avoro Capital Advisors LLC (2.89Mn), VANGUARD GROUP INC (2.78Mn), State Street Corp (1.34Mn), Soleus Capital Management, L.P. (941.06K), Capital World Investors (809.5K), Redmile Group, LLC (677.7K), Hood River Capital Management LLC (613.3K), GEODE CAPITAL MANAGEMENT, LLC (611.88K).